According to a research report published by Spherical Insights & Consulting, the global recombinant vaccine market size was valued at USD 8.2 billion in 2023, and by 2033, the global recombinant vaccine market size is expected to reach USD 24.9 billion. I am. Target companies: AstraZeneca Plc., Dynavax Technologies Corporation, Johnson & Johnson, Merck & Co. Inc., Novovax, Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Abiomed, Emergent Bio Solutions, Inc. GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Daiichi Sankyo, Pifzer, Inc., and other key vendors.
New York, USA, March 11, 2024 (Globe Newswire) — The global recombinant vaccines market size will grow from USD 8.2 billion in 2022 to 24.9 billion by 2032, at a compound annual growth rate (CAGR) of 11.75%. It is expected to grow to US$ billion. During the scheduled period.
Get a sample PDF brochure: https://www.sphericalinsights.com/request-sample/3824
Recombinant vaccines are produced by recombinant DNA technology, which involves inserting desired antigens, including genes from bacteria such as bacterial surface proteins, into viral vectors. When administered internally, similar to natural infections, they enhance the host's antigen-specific immune response. Hepatitis B and HPV are famous examples of recombinant vaccines. The global market for recombinant vaccines is expanding due to the increasing prevalence of infectious diseases, the development of technologically advanced equipment, and the increasing number of regulatory approvals. Additionally, governments are advancing recombinant vaccine efforts in North America, Europe, Latin America, and the Asia-Pacific region. High cost, side effects, and strict regulatory policies of recombinant vaccines are impacting the market. Due to the prevalence of infectious diseases, vaccination rates are increasing. Rising research and development activities and technological advancements are increasing the growth opportunities for the recombinant vaccines market. Advances in cell culture media and improvements in bioreactor design will lead to the development and production of new and more effective vaccines for human and animal health. Vaccine refrigeration is an expensive process, accounting for approximately 80% of the vaccine price. Therefore, rising vaccination costs will limit market growth. Moreover, adverse effects of vaccines and strict regulatory policies are hampering the market.
Browse the report's 110 market data tables and 200 pages of key industry insights, including figures and charts. ”Global recombinant vaccine markett Size and share by type (subunit recombinant vaccine, attenuated recombinant vaccine, vector recombinant vaccine), disease (pneumococcus, cancer, hepatitis B, influenza, DPT, etc.), and end user (pediatrics) and COVID-19 impact analysis, adults) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), 2023-2033 analysis and forecast.
Buy now Full report: https://www.sphericalinsights.com/checkout/3824
subunit recombinant vaccine This segment commands the largest revenue share and dominates the market throughout the forecast period.
Based on type, the global recombinant vaccines market is segmented into subunit recombinant vaccines, attenuated recombinant vaccines, and vector recombinant vaccines. Among these, the subunit recombinant vaccines segment dominates the market with the largest revenue share throughout the forecast period. Recombinant subunit vaccines do not contain live components of pathogenic viruses, which protects against disease risk. Therefore, it is safer and more stable than other types of vaccines.
Hepatitis B segment is witnessing significant CAGR growth throughout the forecast period.
Based on disease, the global recombinant vaccines market is segmented into pneumococcal, cancer, hepatitis B, influenza, DPT, etc. Among these, the hepatitis B segment has witnessed significant growth over the forecast period. The increasing prevalence of hepatitis B in developing and underdeveloped countries is accelerating the demand for hepatitis B vaccines.
adult This segment accounted for the largest share of revenue throughout the forecast period.
Based on end-user insights, the global recombinant vaccines market is segmented into pediatric and adult use. Among these, the adult segment dominates the market with the largest revenue share throughout the forecast period. The rapid increase in the number of adult patients suffering from chronic diseases is accelerating the growth of the recombinant market.
Please contact us before purchasing this research report: https://www.sphericalinsights.com/inquiry-before-buying/3824
North America dominates the market with the largest market share during the forecast period.
North America dominates the market with the largest market share during the forecast period. North America has a high prevalence of chronic diseases, and an increasing number of market participants are entering to increase vaccination rates in the region. The high prevalence of various infectious diseases in the United States, including Abola, Zika, and influenza, presents an excellent opportunity to increase research and development efforts for recombinant vaccines.
Asia Pacific is expected to grow the fastest during the forecast period. The Asia-Pacific region has a high prevalence of infectious diseases as it has highly populated countries such as India and China, thus increasing the number of product launches and other trends adopted by market players.
Competitive analysis:
The report offers pertinent analysis of key organizations/companies involved in the global market along with comparative evaluation mainly based on product offerings, business overview, geographical presence, corporate strategies, segment market shares, and SWOT analysis. . The report also provides an in-depth analysis focusing on the company's current news and developments, including product development, innovation, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and more. This allows you to assess the overall competition within the market. The major vendors in the global recombinant vaccines market are AstraZeneca Plc., Dynavax Technologies Corporation, Johnson & Johnson, Merck & Co. Inc., Novovax, Inc., Sanofi SA, and Serum Institute of India Pvt. Ltd. Ltd., Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Daiichi Sankyo, Pifuser Co., Ltd., and other major companies. .
Get a discount @ https://www.sphericalinsights.com/request-discount/3824
recent trends
-
In April 2022, Candila Pharma has launched a three-dose rabies vaccine called “ThRabis”. This is a novel recombinant nanoparticle-based rabies G protein vaccine developed by virus-like particle technology. The price of the vaccine is RS 715 per dose. Since it is an intramuscular injection, there is little pain.
market segment
This study projects revenues at global, regional and country levels from 2020 to 2032. Spherical Insights segments the global surface transportation market based on the following segments:
Global Recombinant Vaccines Market, Type Analysis
-
subunit recombinant vaccine
-
Attenuated recombinant vaccine
-
vector recombinant vaccine
Global recombinant vaccine market, disease analysis
-
pneumococcus
-
cancer
-
hepatitis B
-
influenza
-
DPT
-
others
Global recombinant vaccine market, end user analysis
Global Recombinant Vaccines Market, Regional Analysis
-
North America
-
Europe
-
Germany
-
England
-
France
-
Italy
-
Spain
-
Russia
-
rest of europe
-
-
Asia Pacific
-
China
-
Japan
-
India
-
South Korea
-
Australia
-
Rest of Asia Pacific
-
-
south america
-
Brazil
-
Argentina
-
rest of south america
-
-
middle east and africa
See related reports
North American companion animal ear infection treatment market sizeshare, and impact analysis of the new coronavirus infection, by product (antibacterial drugs, antifungal drugs, corticosteroids, others), by disease type (otitis externa, otitis media, otitis interna), and by administration method (topical, North America Companion Animal Ear Infection Treatment Market Insights by Animal Type (Dogs, Cats, Others), Country (United States, Canada, Mexico, Rest of North America) and to 2033 prediction
Global animal vaccine market sizeshare, and impact analysis of COVID-19, by product type (attenuated live vaccines, recombinant vaccines, and others), by animal type (livestock, pets, and others), and by route of administration (oral, subcutaneous, intramuscular, intranasal and other), by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), 2023-2033 analysis and forecast
Global gynecological equipment market sizeshare, and COVID-19 impact analysis, by product type (gynecological endoscopy devices, endometrial ablation devices, fluid management systems, female sterilization and contraceptive devices, diagnostic imaging systems) and by application (peritoneal Speculum, Hysteroscopy, DC, Others), End-User (Hospitals, Diagnostic Centers, Others) and Region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), 2023-2033 Analysis and Forecast
US electrosurgical generator market sizeShare, and Impact Analysis of COVID-19, by Product (High Frequency Electrosurgical Generator, Ultrasonic Electrosurgical Generator, Molecular Resonance Electrosurgical Generator, Argon Plasma Electrosurgical Generator, Accessories) , by specialty (urology, gynecology, gastroenterology, ENT, general surgery, other), by end use (hospital, ambulatory surgery center, clinic, other), and electrosurgery in the United States by 2033. Generator Market Insight Forecast
About Spherical Insights & Consulting
spherical insight &consulting is a market research and consulting firm that provides actionable market research studies, quantitative forecasts, and trend analysis, delivering forward-looking insights designed specifically for decision makers to help drive ROI.
We serve a variety of industries including the financial sector, industrial sector, government agencies, universities, non-profit organizations, and corporations. The company's mission is to work with companies to achieve business goals and sustain strategic improvement.
inquiry:
For more information on our target markets, please contact us below.
phone: +1 303 800 4326 (USA)
Phone: +91 90289 24100 (APAC)
Email: contact@sphericalinsights.com, sales@sphericalinsights.com
inquiry: https://www.sphericalinsights.com/contact-us
Please follow us: linkedin | Facebook | twitter
